Citigroup’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-51,551
| Closed | -$2.72M | – | 6239 |
|
|
2026
Q1 | $2.72M | Sell |
51,551
-17,917
| -26% | -$736K | ﹤0.01% | 2461 |
|
|
2025
Q4 | $2.81M | Buy |
69,468
+56,856
| +451% | +$1.31M | ﹤0.01% | 2433 |
|
|
2025
Q3 | $94.7K | Sell |
12,612
-25,662
| -67% | -$164K | ﹤0.01% | 4287 |
|
|
2025
Q2 | $143K | Sell |
38,274
-15,908
| -29% | -$49.7K | ﹤0.01% | 4236 |
|
|
2025
Q1 | $150K | Sell |
54,182
-4,998
| -8% | -$20.4K | ﹤0.01% | 4364 |
|
|
2024
Q4 | $328K | Buy |
59,180
+9,525
| +19% | +$64.5K | ﹤0.01% | 4100 |
|
|
2024
Q3 | $414K | Sell |
49,655
-311,425
| -86% | -$2.56M | ﹤0.01% | 3849 |
|
|
2024
Q2 | $2.46M | Buy |
361,080
+203,519
| +129% | +$1.23M | ﹤0.01% | 2176 |
|
|
2024
Q1 | $1.03M | Buy |
157,561
+150,467
| +2,121% | +$983K | ﹤0.01% | 2999 |
|
|
2023
Q4 | $46K | Buy |
7,094
+6,257
| +748% | +$33.1K | ﹤0.01% | 4567 |
|
|
2023
Q3 | $4.21K | Sell |
837
-13,672
| -94% | -$86.8K | ﹤0.01% | 4759 |
|
|
2023
Q2 | $127K | Sell |
14,509
-30,884
| -68% | -$360K | ﹤0.01% | 4122 |
|
|
2023
Q1 | $537K | Sell |
45,393
-655
| -1% | -$6.26K | ﹤0.01% | 3081 |
|
|
2022
Q4 | $469K | Buy |
46,048
+45,347
| +6,469% | +$302K | ﹤0.01% | 3221 |
|
|
2022
Q3 | $4K | Buy |
701
+182
| +35% | +$676 | ﹤0.01% | 5331 |
|
|
2022
Q2 | $1K | Sell |
519
-548
| -51% | -$1.09K | ﹤0.01% | 6097 |
|
|
2022
Q1 | $3K | Sell |
1,067
-3,219
| -75% | -$13.7K | ﹤0.01% | 5986 |
|
|
2021
Q4 | $30K | Buy |
4,286
+2,694
| +169% | +$22.4K | ﹤0.01% | 5271 |
|
|
2021
Q3 | $17K | Buy |
1,592
+1,177
| +284% | +$12.2K | ﹤0.01% | 5302 |
|
|
2021
Q2 | $5K | Sell |
415
-163
| -28% | -$2.78K | ﹤0.01% | 5853 |
|
|
2021
Q1 | $13K | Buy |
+578
| New | +$12.7K | ﹤0.01% | 5498 |
|
Other funds holding TERN
Citigroup's TERN Position: Q2 2026 in Review
Citigroup sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 51,551 shares — an estimated $2.72M sold.
Citigroup first reported a position in TERN in Q1 2021 and held it in 21 quarters. The position peaked at $2.81M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Citigroup reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citigroup sold 51,551 Terns Pharmaceuticals shares in Q2 2026, an estimated $2.72M.
- Citigroup first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- Citigroup's Terns Pharmaceuticals position peaked at $2.81M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.